RESUMO
BACKGROUND: Nestin is a neural stem cell protein that plays an important role in cancer stem cells (CSC) development and proliferation. It has been identified as a marker for newly formed endothelial cells and was shown to be preferentially expressed in basal and myoepithelial cells of the mammary gland. HOTAIR is long intergenic non-coding (linRNA) associated with tumorigenesis through promotion of epithelial-mesenchymal transition (EMT) and stemness as well. HOTAIR gene contains a functioning single nucleotide polymorphic site rs12826786 C>T that has been associated with several cancer types. METHODS: We evaluated serum Nestin and the HOTAIR rs12826786 C>T polymorphism in healthy Egyptian women and those with breast cancer as a possible screening tool to identify patients with breast cancer. Also, we tested the possible association of the two markers with each other and the aggressiveness of the disease. RESULTS: Patients with breast cancer had a median (Min-Max) of serum Nestin 31.3 (6.7-167.3 pg/mL), while control subjects had a median (Min-Max) of serum Nestin 42.3 (25.7-315.95) pg/mL. The best cut-off value for serum Nestin to differentiate normal subjects and patients with breast cancer was 39.9 pg/mL. This cut-off value had a diagnostic sensitivity of 84.8% and specificity of 65.1%. There was a significant difference in the distribution of different alleles in patients with breast cancer than normal subjects (P=0.039 Exact Fisher test). The breast cancer patients group had 23.9% CC, 52.1% CT, and 23.9% TT genotypes, respectively, while the control group had 46.9% CC, 42.8% CT, and 10.2% TT, respectively. CONCLUSIONS: A significantly low serum Nestin below 39.9 pg/mL and a higher percentage of the T/T homozygous variant allele of HOTAIR rs12826786 C>T were found in Egyptian patients with breast cancer. We suggest that the reported cut-off value of serum Nestin and the presence of C/T polymorphism can be used to assess the risk of females for developing breast cancer and might be of potential benefit in screening the disease. Larger studies in different ethnic groups are needed to confirm our findings.
RESUMO
Breast cancer (BC) is the second leading cause of women's death worldwide. Intercellular adhesion molecule-1 (ICAM-1) is involved in cell-cell interaction, migration and recruitment of immune cells. Polymorphisms in ICAM-1 gene may be involved in BC progression. IFN-gamma inducible protein-10 (IP-10) has the ability to recruit T-cells to induce cellular immunity and may have protective effect against BC development. The current study aimed to shed light on the role of of ICAM-1 SNP and/or serum levels of IP10 in BC in Egyptian female patients and detect possible correlation between these two factors and pathological prognostic markers. 40 breast cancer patients and 40 healthy females were enrolled in the study. Genotyping of ICAM-1 rs281437 SNP was done using real time PCR and serum levels of IP-10 were measured using ELISA. Allelic distribution demonstrated high frequency of ICAM-1 rs281437 CC genotype among BC patients (60%) compared to CT and TT alleles (30% and 10%, respectively). ICAM-1 rs281437 CC genotype showed 9.8 folds more risk to develop BC than other genotypes (95% CI=5.8-21.8, P<0.05). Relation between the studied alleles and hormonal receptors (ER, PR) showed that both ICAM-1 rs281437 CC and CT genotype have 5 folds more to be ER+, PR+ BC compared to TT allele (95% CI=0.21-117.8 and 0.15-125.4, respectively). Serum IP-10 levels were markedly decreased among breast cancer patients when compared with healthy controls (P = 0.001). In conclusion, ICAM-1 rs281437 CC genotype is significantly associated with breast cancer; females carrying CC allele may be at higher risk to develop BC than those carrying CT or TT genotypes. On the other hand, IP-10 may have a protective effect against breast cancer.
